Skip to main content

Table 1 Patient and tumor characteristics in the evaluated cohort and in subgroups according to gender

From: Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study

 

All, n = 527

Female, n = 276 (52.4%)

Male, n = 251 (47.6%)

P valuea

Age

    

   Mean

70.5

70.6

70.4

0.399

   Median

71.4

72

70.9

 

   Range

49.8 to 85.6

49.8 to 85.2

51.8 to 85.6

 

Location

    

   Colon

323 (61.3)

176 (63.8)

147 (58.6)

0.256

   Rectum

190 (36.1)

92 (33.3)

98 (39.0)

 

   Multiple

12 (2.3)

7 (2.5)

5 (2.0)

 

   Unknown

2 (0.4)

1 (0.4)

1 (0.4)

 

T Stage

    

   1

46 (8.7)

31 (11.2)

15 (6.0)

0.506

   2

63 (12.0)

30 (10.9)

33 (13.1)

 

   3

319 (60.5)

159 (57.6)

160 (63.7)

 

   4

78 (14.8)

42 (15.2)

36 (14.3)

 

Unknown

21 (4.0)

39 (12.0)

38 (12.7)

 

N stage

    

   0

278 (52.8)

144 (52.2)

134 (53.4)

0.494

   1

118 (22.4)

68 (24.6)

50 (19.9)

 

   2

85 (16.1)

36 (13.0)

49 (19.5)

 

   Unknown

46 (8.7)

28 (10.1)

18 (7.2)

 

M Stage

    

   0

429 (81.4)

226 (81.9)

203 (80.9)

0.513

   1

90 (17.1)

44 (15.9)

46 (18.3)

 

   Unknown

8 (1.5)

6 (2.2)

2 (0.8)

 

Differentiation grade

    

   High

34 (6.5)

19 (6.9)

15 (6.0)

0.438

   Intermediate

367 (69.6)

185 (67.0)

182 (72.5)

 

   Low

118 (22.4)

67 (24.3)

51 (20.3)

 

   Unknown

8 (1.5)

5 (1.8)

3 (1.2)

 

Vascular invasion

    

   No

150 (28.5)

81 (29.3)

69 (27.5)

0.635

   Yes

156 (29.6)

80 (29.0)

76 (30.3)

 

   Unknown

222 (41.9)

115 (41.7)

106 (42.2)

 

Surgery

    

   Acute

46 (8.7)

26 (9.4)

20 (8.0)

0.502

   Elective

454 (86.1)

233 (84.4)

221 (88.0)

 

   Unknown

27 (5.1)

17 (6.2)

10 (4.0)

 

Neodjuvant treatment

    

   None

414 (78.6)

216 (83.4)

198 (82.2)

0.291

   Short RT

25 (4.7)

10 (3.9)

15 (6.2)

 

   Long RT

19 (3.6)

8 (3.1)

11 (4.6)

 

   Chemotherapy + RT

2 (0.4)

2 (0.8)

0 (0.0)

 

   Chemotherapy

2 (0.4)

1 (0.4)

1 (0.4)

 

   Unknown

65 (12.3)

39 (14.1)

16 (10.4)

 

Adjuvant treatment

    

   No

294 (55.8)

149 (54.0.8)

145 (57.8)

0.584

   FLV/Xeloda

51 (9.7)

25 (9.1)

26 (10.4)

 

   FLOX/XELOX

19 (3.6)

11 (4.0)

8 (3.2)

 

   Other

5 (0.9)

4 (1.4)

1 (0.4)

 

   Curative; M1*

14 (2.7)

6 (2.2)

8 (3.2)

 

   Palliative

80 (15.2)

39 (14.1)

41 (16.3)

 

   Unknown

64 (12.1)

42 (15.2)

22 (8.8)

 

Follow-up (years)

    

   Mean

4.7

4,9

4.5

0.399

   Median

3.5

3.4

3.4

 

   Range

0.0 to 17.7

0.0 to 17.7

0.0 to 16.6

 

Vital status

    

   Alive

306 (58.1)

169 (61.2)

137 (54.6)

0.113

   Dead

221 (41.9)

107 (38.8)

114 (45.4)

 

   Dead from CRC

182 (34.5)

90 (32.6)

92 (36.7)

0.313

Follow-up (years); M1 patients

    

   Mean

1.5

1.3

1.6

0.129

   Median

1.1

0.8

1.2

 

   Range

0.0 to 6.1

0.0 to 5.5

0.0 to 6.1

 

Vital status; M1 patients

    

   Alive

12 (13.3)

7 (15.9)

5 (10.9)

0.484

   Dead

78 (86.7)

37 (84.1)

41 (89.1)

 

   Dead from CRC

78 (86.7)

37 (84.1)

41 (89.1)

0.484

Cyclin D1 fraction

    

   0 to 1

105 (19.9)

50 (18.1)

55 (21.9)

0.217

   02 to 25

195 (37.0)

100 (36.2)

95 (37.8)

 

   26 to 50

86 (16.3)

48 (17.4)

38 (15.1)

 

   51 to 75

112 (21.3)

64 (23.2)

48 (19.1)

 

   > 75

29 (5.5)

14 (5.1)

15 (6.0)

 

Cyclin D1 intensity

    

   Negative

105 (19.9)

50 (18.1)

55 (21.9)

0.018

   Weak

181 (34.3)

85 (30.8)

96 (38.2)

 

   Moderate

176 (33.4)

102 (37.0)

74 (29.5)

 

   Strong

65 (12.3)

39 (14.1)

26 (10.4)

 
  1. aThe P values refer to comparisons of male and female tumors, using the Mann-WhitneyU-test for comparison of medians and the χ2 test for X × 2 tables. P-values for vital status refer to overall and cause-specific death, respectively. The categories marked as 'not done' and 'unknown' were not included in the statistical analysis.
  2. Abbreviations: FLOX = 5-fluorouracil, leucovorin and oxaliplatin, FLV = 5-fluorouracil and leucovorin, RT = radiotherapy, XELOX = Xeloda (capecitabine) and oxaliplatin.